Saci-IO TNBC: Randomized phase II study of sacituzumab govitecan with or without pembrolizumab in PD-L1-negative metastatic triple negative breast cancer (TNBC)
ENROLLING
Trial ID:
NCT04468061 Protocol # :
20-166
Phase
II
Disease Sites
Breast
Principal Investigator
Garrido-Castro, Ana, C.
Site Research Nurses
Bowers, Jordan
Brule, Maurice, N.
Caradonna, Lisa
Casella, Allison
Cronis, Charles, Lewis
Cung, Connie
Fleming, Norah, Michelle
Freeman, Stefani, Danielle
Gentile, Alissa
Ginter, Lindsey
Hixon, Nicole, R.
Houghton, Nicole
Jeon, Maryangel, H.
Kasparian, Elizabeth
Kosinski, Michelle
Kuhlman, Rachel
Loeser, Wendy
Macauley, Colleen
Miles, Brandy
Orechia, Meghan
Patel, Nikita
Piper, Audrey, L.
Quinn, Caroline
Roche, Kathleen, A.
Rutter, Morgan
Seaward, Meghan
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #20-166
20-166